Study of a new treatment for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new investigational drug called BETA-TT8 for people with wet age-related macular degeneration (wet AMD) who have already been treated with standard therapy (aflibercept). The goal is to see if this new treatment is safe and effective in improving vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with wet age-related macular degeneration (wet AMD) and have already received at least three treatments with aflibercept (Eylea) in the affected eye.
- You are generally in good health and do not have severe eye conditions that would interfere with the study.
- You have no uncontrolled heart rhythm problems, recent cancer (except certain skin cancers or fully treated prostate/breast cancer), or are not pregnant or breastfeeding.
- You are able to self-administer eye drops or have a caregiver who can do this at home, and you can commit to the study visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.